Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 5:55 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 653 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Total Cholesterol Clear all

Conditions: Atherosclerosis, Cardiovascular Disease, Hypercholesterolemia
Interventions: VERVE-102, Placebo; Drug
Lead sponsor: Verve Therapeutics, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 175 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: DeSoto, Texas

Conditions: Epilepsy, Dyslipidemia
Interventions: Atorvastatin 10mg, Modification of dietary fat composition; Drug · Other
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Gestational Diabetes, Hyperlipidemia
Interventions: Total Cholesterol, Triglyceride, HDL, LDL; Other
Lead sponsor: Baystate Medical Center; Other
Eligibility: 16 Years to 40 Years · Female only
Enrollment: 106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Springfield, Massachusetts

Conditions: Obsessive-Compulsive Disorder
Interventions: Psilocybin (0.25mg/kg), Niacin (250mg); Drug
Lead sponsor: Yale University; Other
Eligibility: 21 Years to 65 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Schizophrenia, Schizoaffective Disorders, Schizophreniform Disorders
Interventions: Pravastatin, Placebo; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 68 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Hypercholesterolemia, Familial
Interventions: ISIS 301012; Drug
Lead sponsor: Kastle Therapeutics, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 5
States / cities: Chicago, Illinois • New York, New York • Winston-Salem, North Carolina + 2 more

Conditions: Peripheral Arterial Disease
Interventions: Ezetimibe, Niaspan, Statin therapy, Standard care, Aspirin, Clopidogrel, Placebo Niaspan, Placebo Ezetimibe, Percutaneous transluminal angioplasty (PTA); Drug · Behavioral · Procedure
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 40 Years to 80 Years
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2010
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Type 2 Diabetes Mellitus
Interventions: pioglitazone; Drug
Lead sponsor: University of Miami; Other
Eligibility: 35 Years to 70 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Physical Disability
Interventions: EnhanceWellness for Disability (EW-D), Wellness Education; Behavioral
Lead sponsor: University of Washington; Other
Eligibility: 45 Years to 64 Years
Enrollment: 516 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Primary Hypercholesterolemia, Mixed Dyslipidemia
Interventions: Evolocumab Pre-filled Syringe, Evolocumab AI/pen; Biological
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 149 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2013
U.S. locations: 21
States / cities: Encino, California • Thousand Oaks, California • Ventura, California + 17 more

Conditions: Elevated HMB Excretion
Interventions: Statin user; Other
Lead sponsor: Texas A&M University; Other
Eligibility: 65 Years to 80 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: College Station, Texas

Conditions: Familial Hypercholesterolaemia
Interventions: Alert-based computerized decision support; Device
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: Not listed
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Coronary Artery Disease
Interventions: NCEP Step 1 diet plus Almonds, No Almonds; Other
Lead sponsor: Boston University; Other
Eligibility: 21 Years to 80 Years
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Breast Cancer, Early-stage Breast Cancer
Interventions: Prescreening, Screening and Enrollment, Baseline, Interpret BMI, Interpret HbA1c, Interpret lipid panel and assess other risk factors, Assess 10 year risk of cardiovascular event, Recommendations, Follow-Up; Other · Behavioral
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Hypercholesterolemia, Atherosclerotic Cardiovascular Diseases
Interventions: ETC-1002, Placebo; Drug
Lead sponsor: Esperion Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 2,230 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 48
States / cities: Huntsville, Alabama • Cottonwood, Arizona • Phoenix, Arizona + 45 more

Conditions: Cardiovascular Disease
Interventions: Mobile Health Application, Environmental Cues, Social Support, Educational Materials; Behavioral
Lead sponsor: Northwestern University; Other
Eligibility: 17 Years to 26 Years
Enrollment: 302 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Breast Cancer
Interventions: Lovastatin; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 1
States / cities: Stanford, California

Conditions: Hypercholesterolemia
Interventions: alirocumab, Placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: New York, New York

Conditions: Prediabetes, Diabetes, High Cholesterol/Hyperlipidemia, Obesity & Overweight, Triglycerides, HDL Cholesterol
Interventions: Bottarga, Comparator; Other
Lead sponsor: Cambridge Health Alliance; Other
Eligibility: 18 Years to 60 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Sommerville, Massachusetts

Conditions: Cholesterol
Interventions: Added Cholesterol, No Added Cholesterol; Dietary Supplement · Other
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years to 70 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Bipolar Disorder, Major Depressive Disorder
Interventions: Pregnenolone, Placebo; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Type 2 Diabetes Mellitus
Interventions: Low Glycemic Diet, Control Diet; Other
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 35 Years to 65 Years
Enrollment: 65 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Severe Hypertriglyceridemia
Interventions: Olezarsen, Placebo; Drug
Lead sponsor: Ionis Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 617 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 56
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Chula Vista, California + 51 more

Conditions: Obesity
Interventions: Y288; Dietary Supplement
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years to 65 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Sacramento, California

Search by objective public record fields.

A Study of VERVE-102 (LY4636581) in Adults With or at High Risk for Cardiovascular Disease

Improving Cardiovascular Health Risks in Adults With Epilepsy on a Modified Atkins Diet

Lipid Metabolism in Gestational Diabetes

Efficacy of Psilocybin in OCD: a Double-Blind, Placebo-Controlled Study.

Effects of Pravastatin on Cholesterol, Inflammation and Cognition in Schizophrenia

Dose-escalating Safety Study of ISIS 301012 in Homozygous Familial Hypercholesterolemia Subjects on Lipid Lowering Therapy

Effectiveness of Intensive Lipid Modification Medication in Preventing the Progression of Peripheral Arterial Disease (The ELIMIT Study)

Effects of Pioglitazone on High-density Lipoprotein (HDL) Function in Persons With Diabetes

A Community Wellness Program for Adults Living With Long-term Physical Disability

Study to Assess In-home Use of Evolocumab (AMG 145) Using a Prefilled Syringe or a Prefilled Autoinjector/Pen

Cholesterol and Statin in Healthy Adults

Computerized Decision Support for Identification and Management of Familial Hypercholesterolemia

Effects of Almonds On Endothelial Function In Patients With Coronary Artery Disease

Cardiometabolic Screening Program

Evaluation of Long-Term Safety and Tolerability of ETC-1002 in High-Risk Patients With Hyperlipidemia and High CV Risk (CLEAR Harmony)

NUYou:mHealth Intervention to Preserve and Promote Ideal Cardiovascular Health

Phase 2 Study of Lovastatin as Breast Cancer Chemoprevention

Effect of Alirocumab on Lipid Metabolism in Adults With Elevated LDL-Cholesterol

Pilot Study of "Bottarga" Supplementation: A Little-known, Sustainable "Blue" Food

Dietary Cholesterol and Adipose Tissue Inflammation

Study Using Pregnenolone to Treat Bipolar Depression

Return of First-phase Insulin Secretion in Type 2 Diabetes is Associated With Depletion of Pancreas Lipid

A Study of Olezarsen (ISIS 678354) Administered to Participants With Severe Hypertriglyceridemia

Compare Effects of a Soluble Fiber on Weight and Blood Cholesterol